Solid Biosciences Inc (NASDAQ:SLDB) CEO Ilan Ganot sold 11,124 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $2.42, for a total value of $26,920.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of NASDAQ:SLDB opened at $2.63 on Friday. The business’s fifty day moving average price is $2.98 and its two-hundred day moving average price is $2.97. The stock has a market cap of $120.70 million, a PE ratio of -0.99 and a beta of 1.26. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.50 and a current ratio of 4.50. Solid Biosciences Inc has a one year low of $1.96 and a one year high of $13.58.
Solid Biosciences (NASDAQ:SLDB) last announced its earnings results on Thursday, May 7th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.08. As a group, equities research analysts predict that Solid Biosciences Inc will post -1.67 earnings per share for the current fiscal year.
A number of analysts have weighed in on the company. SVB Leerink cut Solid Biosciences from an “outperform” rating to a “market perform” rating and set a $3.00 price objective for the company. in a research report on Monday, July 27th. Chardan Capital reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Solid Biosciences in a research note on Saturday, May 9th. Finally, Nomura reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Solid Biosciences in a research note on Thursday, May 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. Solid Biosciences has a consensus rating of “Hold” and a consensus price target of $7.38.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.
Further Reading: Trading based on a resistance level
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.